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Objective: To investigate whether change in concentrations over time of aggrecanase generated ARGS-
aggrecan in synovial ﬂuid (SF ARGS) associates with progression of radiographic knee osteoarthritis
(OA) and patient-reported outcome in subjects with previous meniscectomy.
Methods: We studied 141 subjects at two time points after meniscectomy. Time point A was on average
18 years after meniscectomy, time point B was on average 7.5 years later; 74 subjects had SF available
from both examinations. We measured SF ARGS by an electrochemiluminescence immunoassay, graded
radiographic features of tibiofemoral or patellofemoral OA according to the Osteoarthritis Research
Society International (OARSI) atlas, and scored patient-reported outcomes using the Knee Injury and
Osteoarthritis Outcome Score (KOOS). Using logistic regression (adjusted for age, gender, body mass
index, time between examinations, and SF ARGS at ﬁrst examination) we assessed associations between
change in SF ARGS between ﬁrst and second examinations and progression of radiographic OA and KOOS.
Results: In subjects with decreasing SF ARGS between examinations, the likelihood of loss of joint space
and worsening of KOOS pain between examinations was increased 6- and 4-fold respectively compared
to those increasing in SF ARGS (odds ratio (OR) 5.72; 95% conﬁdence interval (CI) 1.53e21.4 and 3.66;
1.01e13.2, respectively). No signiﬁcant associations were seen between decreasing SF ARGS and
progression of osteophytes (OR 0.88; 0.28e2.78), or for patient-reported outcomes other than KOOS pain.
Conclusion: Having decreasing levels of SF ARGS over time was associated with an increased risk of loss of
joint space and pain worsening, but showed no association with other patient-reported outcomes or
osteophyte progression.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is distinguished by loss of cartilage, alter-
ations of subchondral bone, formation of osteophytes, and is
associated with pain and function limitations1. Much effort has
been put into the development of OA biomarkers in search of tools
to enable earlier diagnosis and prognosis2,3.
Aggrecan is a major constituent in articular cartilage and is of
crucial importance for load distribution and shock-absorption. Twoto: Staffan Larsson, Lund
, SE-221 84 Lund, Sweden.
n),martin.englund@med.lu.se
, stefan.lohmander@med.lu.se
s Research Society International. Paggrecanolytic enzymes with increased expression and activity in
pathology are the aggrecanases a disintegrin and metalloprotease
with thrombospondin motifs (ADAMTS-4) and ADAMTS-5 (also
known as aggrecanase 1 and 2, respectively)4. They both cleave
aggrecan at the Glu392-Ala393 bond (amino acid numbering based
on the accession number [Swiss-Prot: P16112] for human aggrecan)
in the interglobular domain resulting in the release of aggrecan
393ARGS-neoepitope fragments carrying the majority of the ﬁxed
negative charges of aggrecan.
Joint injury predisposes individuals to develop OA5e8. We have
shown that the release from cartilage into synovial ﬂuid (SF) of
aggrecanase generated ARGS-aggrecan is highly elevated after knee
trauma, and then with time gradually reverts toward normal
levels9,10. We have further reported that 18 years after a meniscus
injury treated by meniscectomy, SF levels of ARGS-aggrecan are noublished by Elsevier Ltd. All rights reserved.
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concentrations within these relatively normal levels were associ-
ated with less progression of radiographic knee OA (ROA) over the
next 4e10 years11. Our proposed hypothesis for this associationwas
an effect of higher levels of aggrecan synthesis in combinationwith
aggrecanase activity, leading to both an increased release of ARGS
into SF and a net beneﬁcial incorporation into cartilage11.
The primary aim of the present study was therefore to investi-
gate if changes in SF levels of ARGS-aggrecan over 4e10 years were
associated with progression of ROA. We hypothesised that indi-
viduals with decreasing levels of SF ARGS over time would have an
increased risk of ROA progression. A secondary aim was to inves-
tigate whether SF ARGS levels, or change in those levels over time,
were associated with changes in patient-reported outcomes, using
the Knee Injury and Osteoarthritis Outcome Score (KOOS)12,13.Materials and methods
Materials
Chemicals were as described14. Human recombinant ADAMTS-
415 and monoclonal antibody (MAb) OA-1 were from Glax-
oSmithKline (Collegeville, PA, USA). MAb AHP0022 against human
aggrecan was from Invitrogen (Carlsbad, CA, USA). High bind
MA600 96-well microtitre plates (no. L11XB-1), streptavidin with
Sulfo-Tag (streptavidin tagged with the reporter molecule ruthe-
nium (II) tris-bipyridyl, no. R32AD), 4 Read Buffer T with surfac-
tant (no. R92TC) and the Sector Imager 6000 with software
Discovery Workbench 2006 MSD_3_0_18 were from Meso Scale
Discovery (MSD, Gaithersburg, MD, USA).Subjects
The study was approved by the ethics committee of the Faculty
of Medicine at Lund University; informed consent was obtained
from all participants. Subjects were from a cohort of 317 patients,
retrospectively identiﬁed to have undergone isolated meniscec-
tomy at Lund University Hospital in 1973,1978 or 1983e198516. The
ﬁrst examinations (A) were performed 1994, 1995 and 2000,
respectively, and the second examination (B) in 2004. The mean
(range) time from meniscectomy to examination A was 18 (15e22)
years and the time between examinations A and B was 7.5 (4e10)
years (Fig. 1). As described16, reasons for exclusion were previous
knee surgery, meniscectomy in both knee compartments, osteo-
chondritis dissecans, fracture in or adjacent to the knee, septic
arthritis, osteonecrosis, any ligament injury, or radiographic signs
of knee OA at time of surgery. Out of 859 identiﬁed subjects, 456
fulﬁlled criteria and were invited to participate at examination
A, 329 responded and 317 had radiographs taken. Here we further
excluded subjects with end-stage OA (deﬁned below) of the index
knee at examination A. Out of the 317 available subjects, 141 had
complete radiographic and demographic data, and SF at examina-
tion A; thesewere included as the Study cohort n¼ 141 (Fig. 2) with
characteristics as described11. Of the included 141 subjects with SFFig. 1. A visit and sample timeline over the study.at examination A, a subset of 74 had SF available also from exam-
ination B in average 7.5 years later and were studied as Subset
n¼ 74 for investigation of longitudinal change in SF levels of ARGS-
aggrecan (Fig. 2). Characteristics of Subset n¼ 74 is presented in
Table I. Based on the previously noted association between SF ARGS
at examination A and loss of joint space between examination
A and examination B11, the subjects in Subset n¼ 74 were also
stratiﬁed for increasing or decreasing SF ARGS levels from exami-
nation A to examination B (Table I).
Radiographic examination
Radiographs of the tibiofemoral (TF) and patellofemoral (PF)
joints were obtained as described11. Joint space narrowing (JSN)
and osteophytes in the TF and PF joints were graded on a four point
scale (0e3, where 0¼ no evidence of JSN or osteophytes) according
to the 1995 atlas of Osteoarthritis Research Society International
(OARSI)17,18, as described11. We considered progression of JSN,
osteophytes, or their sum (progression of ROA) to have occurred
with an increase from examination A to examination B of the
respective scores by one or more in any of the TF compartments or
the PF compartment. This includes both incident JSN and osteo-
phytes at examination B and worsening of already existing
changes11.
ROA
A knee was deﬁned as having ROA with any of the following:
1. JSN in any TF compartment or the PF compartment grade 2
2. Sum of marginal osteophyte grades in the medial or lateral TF
compartment or the PF compartment 2
3. JSN grade 1 and osteophyte grade 1 in the same TF compart-
ment or JSN grade 1 and osteophyte grade 1 in the PF
compartment
This cut-off approximates grade 2 TF OA on the Kellgren and
Lawrence (K/L) scale18.
End-stage OA
A knee was considered to have end-stage ROA either (1) with
JSN grade 3 in any of the TF compartments or in the PF compart-
ment, or (2) when a subject had undergone subsequent tibial
osteotomy or arthroplasty for OA.
Self-reported patient-relevant outcomes by KOOS
For assessment of patient-relevant outcomes we used the self-
administered questionnaire KOOS12,13. The KOOS questionnaire
covers the ﬁve patient-relevant dimensions pain, other symptoms,
function of daily living, function in sports and recreation, and knee-
related quality of life, with scores ranging from 0 (worst) to 100
(best)12,13, and was scored according to the instructions on the
KOOS home page19. A decline between examinations by 10 units or
more was used as cut-off for a clinically relevant progression in all
subscales20. Our primary outcome for patient-relevant outcomes
was progression in KOOS pain by 10 units or more, but we also
studied progression in the other four KOOS dimensions.
Measurement of ARGS-aggrecan by aggrecan capture OA-1 ARGS
electrochemiluminescence (ELCL) assay
SF samples were aspirated (without lavage) from the index knee
joint of patients with previous meniscectomy. The ﬂuids were at
the time of aspiration centrifuged at 3,000 g, with the supernatants
stored at 80C. SF concentrations of aggrecan fragments
Table I
Characteristics and outcome measures in Subset n¼ 74, subjects with SF at both examination A and B
Subset n¼ 74 Stratiﬁed for longitudinal change in SF ARGS
SF ARGS A< B SF ARGS A>B P-value
n¼ 74 n¼ 44 n¼ 30
Characteristics
Men 61 (82%) 34 (77%) 27 (90%) 0.16
Age at examination A, years 50 (32e73) 52 (35e73) 49 (32e69) 0.22
BMI at examination A, kg/m2 26 (18e41) 26 (18e33) 27 (22e41) 0.26
Years between index surgery and examination A 18 (15e22) 17 (15e22) 19 (15e22) 0.018
Years between examinations A and B 7.5 (4.0e10.3) 7.1 (4.0e10.1) 8.2 (4.0e10.3) 0.068
SF ARGS concentrations
SF ARGS at examination A, pmol ARGS/ml 6.66 (0.15e14.58) 5.59 (0.15e12.79) 8.24 (3.05e14.58) <0.001
SD 3.28 SD 2.82 SD 2.91
SF ARGS at examination B, pmol ARGS/ml 7.06 (0.12e14.71) 7.68 (1.46e14.71) 6.15 (0.12e10.74) 0.029
SD 2.97 SD 3.11 SD 2.55
Radiographic status at examinations
ROA at examination A 41 (55%) 23 (52%) 18 (60%) 0.51
ROA at examination B 57 (77%) 31 (70%) 26 (87%) 0.10
End-stage OA at examination B 18 (24%) 9 (20%) 9 (30%) 0.35
Radiographic progression
Loss of joint space/Progression of the JSN score 41 (55%) 20 (46%) 21 (70%) 0.037
Osteophyte progression 34 (46%) 20 (46%) 14 (47%) 0.92
ROA progression 52 (70%) 27 (61%) 25 (83%) 0.042
KOOS score progression (worsening by 10 units)
Pain 23 of 69 (33%) 10 of 41 (24%) 13 of 28 (46%) 0.057
Other symptoms 24 of 71 (34%) 12 of 42 (29%) 12 of 29 (41%) 0.26
Function of daily living 18 of 69 (26%) 9 of 41 (22%) 9 of 28 (32%) 0.34
Function in sports and recreation 31 of 69 (45%) 16 of 40 (40%) 15 of 29 (52%) 0.33
Knee-related quality of life 25 of 71 (35%) 16 of 42 (38%) 9 of 29 (31%) 0.54
Values are numbers (%) ormean (range). P-values are by Pearson’s Chi-square test for comparisons of frequencies, respectively Student’s t test for comparisons of means. ARGS,
aggrecan neoepitope amino acid sequence..
Fig. 2. Flowchart of inclusion and exclusion of subjects in the study cohort and in the subset.
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technology21 on the MSD platform recently developed in our
laboratory11. It is an assay that uses an anti-human aggrecan
capture antibody (AHP0022, Invitrogen), reactive against the
globular domains 1 and 2 (G1 and G2) of human aggrecan, in
combination with the MAb OA-122, speciﬁc for the ARGS-
neoepitope within the interglobular domain of aggrecan. The
assay and its evaluation has been described in detail11. Brieﬂy, 25 ml
aliquots of SF samples were, after deglycosylation, analysed for
ARGS-content against a standard of ADAMTS-4 digested and
deglycosylated human cartilage A1D1 aggrecan. Samples from
examinations A and B were analysed separately but directly
following each other over a period of 4 months using the same
batches of standard, high bind 96-well microtitre MSD plates, and
antibodies. Data for SF ARGS at examination A has been previously
published in a study using these samples11. Inter and intra assay
coefﬁcients of variations were as reported11.
Statistical analysis
We used the Shapiro-Wilk test to assess normal distribution of
SF ARGS, Pearson’s correlation (r) for normally distributed contin-
uous variables and Spearman’s rank order correlation (rS) when
categorical variables were included. For comparison of SF ARGS
between examinations A and B we used a paired samples t test. For
group comparison of SF ARGS in males and females we used anal-
ysis of covariance (ANCOVA) with or without adjustments for age,
body mass index (BMI), and time between meniscectomy and
examination A; for other group comparisons of means we used
Student’s t test. We used Pearson’s Chi-square test for comparisons
of frequencies between groups.
For analysis of longitudinal associations between SF ARGS and
progression of ROA and KOOS we used univariate and multivariate
logistic regression. For analysis of associations between SF ARGS at
either examination and progression of ROA and KOOS, odds ratios
(ORs) were calculated without adjustments (crude) or with
adjustments for age, gender, BMI, and time between examinations
A and B, with the reported ORs reﬂecting an incremental increase of
1 pmol ARGS/ml. To study the association between the change in
levels of SF ARGS between examinations and progression of ROA
and KOOS, we created a dichotomous SF ARGS variable; increase or
decrease. In addition to the adjustments above, in the ﬁnal model
we also adjusted for SF ARGS levels at examination A11. We
considered P below 0.05 to be signiﬁcant. All tests were two-tailed
and performed using SPSS (Chicago, IL, USA) for Windows, version
17.0.0.
Results
Subject characteristics
Analyses were made on all subjects with SF available from
examination A (Study cohort n¼ 141), and on the subset of subjectsTable II
Self-reported KOOS data at examinations A and B
Study cohort n¼ 141
Examination A E
Pain 88 (17) 8
Other symptoms 86 (15) 8
Function of daily living 89 (15) 8
Function in sports and recreation 67 (30) 6
Knee-related quality of life 76 (24) 7
Values are mean (SD). There were no statistically signiﬁcant differences in KOOS dimenswith SF available also from examination B (Subset n¼ 74) (Fig. 2).
Characteristics of Study cohort n¼ 141 have been described11;
characteristics of Subset n¼ 74 are presented in Table I. Self-
reported patient-relevant outcomes (KOOS) for all 141 subjects
and for the Subset n¼ 74 are presented in Table II. No statistically
signiﬁcant differences were noted between the larger Study cohort
and the Subset regarding patient characteristics, radiographic
status and KOOS scores at either examination, or change in radio-
graphic status and KOOS scores from examination A to examination
B, nor between the 67 subjects lacking SF at examination B and the
Subset n¼ 74 (not shown).
SF ARGS-aggrecan: gender differences and correlations
We found SF ARGS at examinations A and B to be normally
distributed (P¼ 0.65 and 0.85, respectively). In this sample and
time frame (range 15e22 years) we found no signiﬁcant correlation
between SF ARGS and time from meniscectomy (P¼ 0.36). In the
Subset n¼ 74 with SF samples available from both examinations, SF
ARGS concentrations showed a correlation between examinations
[Fig. 3(A)], and the mean concentrations did not differ signiﬁcantly
between examinations (6.66 and 7.06 pmol ARGS/ml at examina-
tions A and B, respectively; P¼ 0.21; Table I). In longitudinal change
in SF ARGS from examination A to examination B, those with higher
levels at examination A tended to decrease, and those with lower
levels at examination A tended to increase [Fig. 3(B)].
As reported, there was a signiﬁcantly higher concentration of SF
ARGS at examination A inmen compared with women in thewhole
Study cohort n¼ 14111. At examination B (in Subset n¼ 74), no
statistically signiﬁcant gender differences in SF ARGS were
observed, with concentrations in men and women being 7.14
(0.12e14.71) and 6.69 (2.63e10.05) pmol ARGS/ml, respectively.
BMI was higher in men at both examinations (P< 0.001 examina-
tion A, P¼ 0.002 examination B) with mean (range) values for men
and women being 26.6 (22.2e41.0) kg/m2 and 22.7 (17.9e27.3)
kg/m2 at examination A, and 28.1 (23.0e40.4) kg/m2 and 24.4
(16.9e31.5) kg/m2 at examination B. No correlation was, however,
observed between SF ARGS and BMI at either examination (not
shown). We found no correlation between SF ARGS and individual
or summed scores of radiographic features of OA or patient-
relevant outcomes in the KOOS instrument at examination
A (n¼ 141) or at examination B (n¼ 74) (data not shown).
SF ARGS-aggrecan and its association with progression of
radiographic features of OA
Examination A levels of SF ARGS
As reported11, a weak inverse association between SF ARGS
concentration at examination A and loss of joint space from
examination A to examination B was present in the larger Study
cohort n¼ 141 (Table III). Associations in Subset n¼ 74 were
essentially the same, with ORs 0.90, 0.95, and 0.87 for loss of joint
space, osteophyte progression and progression of ROA, respectively,Subset n¼ 74
xamination B Examination A Examination B
2 (19) 89 (15) 83 (17)
0 (20) 87 (13) 81 (18)
6 (18) 91 (14) 87 (16)
2 (32) 69 (28) 63 (33)
0 (26) 78 (21) 71 (26)
ions between the Study cohort and the Subset.
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Fig. 3. SF ARGS at examinations A and B. (A) Scatter plot showing the linear relationship between SF ARGS at examination A and examination B with Pearson’s correlation coefﬁcient
(r) indicated. Solid line shows the ﬁrst order regression; dotted line denotes the line of equality. (B) Bland-Altman plot of the difference of SF ARGS between examinations against SF
ARGS at examination A. Pearson’s correlation coefﬁcient (r) is indicated for the solid regression line.
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(not shown) and the cross-sectional association with loss of joint
space was no longer signiﬁcant.
Examination B levels of SF ARGS
The examination B levels of SF ARGS in Subset n¼ 74 were
inversely associated with loss of joint space from examination A toTable III
Progression of outcomes and their associationwith levels of SFARGS-aggrecan, and decrea
SF ARGS at A
Study cohort n¼ 141
OR P
Radiographic progression
Loss of joint space/progression of the JSN score 0.89 (0.80e0.99)* 0.
0.89 (0.79e0.996)* 0.
Osteophyte progression 0.96 (0.87e1.07)* 0.
0.97 (0.87e1.08)* 0.
ROA progression 0.90 (0.80e1.00)* 0.
0.89 (0.78e1.02)* 0.
KOOS progressiony
Pain 0.94 (0.84e1.06) 0.
0.94 (0.84e1.06) 0.
Other symptoms 1.02 (0.91e1.14) 0.
1.04 (0.92e1.18) 0.
Function of daily living 1.01 (0.89e1.14) 0.
1.01 (0.88e1.15) 0.
Function in sports and recreation 1.06 (0.95e1.18) 0.
1.07 (0.95e1.20) 0.
Knee-related quality of life 1.00 (0.90e1.12) 0.
1.01 (0.90e1.13) 0.
Radiographic outcomes (loss of joint space, osteophyte progression, and ROA progression
osteophytes, and either JSN or osteophytes or both, scored according to the OARSI atlas1
was deﬁned as a worsening in the respective score by 10 units or more18. OR and P-value
A and B (plain text), or with adjustment for age, gender, BMI, and time between examinat
in parentheses.
* Associations between SF ARGS at examination A and progression of radiograph
2010;12:R23011.
y n for KOOS scores varies between 132 and 136 for the larger Study cohort, and betwexamination B (odds ratio (OR) 0.78; Table III), and with
progression of ROA from examination A to examination B (OR
0.73; Table III), where higher SF ARGS levels decreased the risk of
radiographic progression. Although the logistic regression analysis
showed ORs below one also for SF ARGS at examination B and
osteophyte progression up to examination B, no signiﬁcant asso-
ciation was seen (Table III).sing levels of SFARGS-aggrecan between examinations by logistic regression analysis
SF ARGS at B SF ARGS A > B
Subset n¼ 74 Subset n¼ 74
OR P OR P
029 0.78 (0.65e0.93) 0.007 2.80 (1.05e7.47) 0.040
043 0.78 (0.64e0.95) 0.012 2.90 (0.98e8.58) 0.055
5.72 (1.53e21.4) 0.010
48 0.89 (0.76e1.05) 0.17 1.05 (0.41e2.66) 0.92
59 0.89 (0.74e1.06) 0.19 0.79 (0.28e2.25) 0.66
0.88 (0.28e2.78) 0.84
059 0.77 (0.63e0.93) 0.007 3.15 (1.01e9.80) 0.048
10 0.73 (0.58e0.93) 0.010 3.15 (0.84e11.8) 0.089
6.77 (1.38e33.2) 0.018
32 0.89 (0.74e1.07) 0.22 2.69 (0.96e7.52) 0.060
31 0.88 (0.72e1.08) 0.22 3.03 (0.95e9.62) 0.061
3.66 (1.01e13.2) 0.048
75 1.04 (0.88e1.23) 0.66 1.76 (0.65e4.78) 0.26
53 1.08 (0.88e1.31) 0.47 1.41 (0.43e4.58) 0.57
1.06 (0.29e3.88) 0.92
88 1.05 (0.88e1.26) 0.58 1.68 (0.57e4.98) 0.35
93 1.04 (0.84e1.30) 0.72 1.14 (0.31e4.20) 0.85
1.11 (0.26e4.80) 0.88
33 1.04 (0.88e1.23) 0.66 1.61 (0.61e4.22) 0.35
29 1.05 (0.87e1.27) 0.60 1.43 (0.47e4.38) 0.53
1.22 (0.36e4.12) 0.75
94 1.08 (0.92e1.28) 0.36 0.73 (0.27e1.99) 0.54
85 1.15 (0.95e1.40) 0.16 0.39 (0.12e1.35) 0.14
0.29 (0.072e1.18) 0.083
) are based on progression from examination A to examination B of the scores of JSN,
6. Worsening of patient-relevant outcomes was assessed by KOOS12,13; progression
s are crude (italics) or adjusted for age, gender, BMI, and time between examinations
ions A and B, and SF ARGS at examination A (bold text), with 95% conﬁdence interval
ic features of OA was previously published in Larsson et al. Arthritis Res Ther
een 69 and 71 for the Subset.
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In subjects who decreased in SF ARGS-aggrecan from exami-
nation A to examination B, the likelihood for loss of joint space
between examinations was increased 3-fold compared to those
increasing in SF ARGS (crude OR 2.80; Table III). Including adjust-
ments for age, gender, BMI and time between visits did not
essentially alter this estimate of risk, but including adjustments
also for SF ARGS concentration at examination A increased the
point estimate further (adjusted OR 5.72; Table III).
With ORs around one, decreasing SF ARGS did not show an
association with osteophyte progression (Table III).
In subjects with decreasing SF ARGS, the risk of progression of
the combination of loss of joint space and osteophytes (ROA
progression) was essentially the same as the risk for loss of joint
space alone (Table III).
SF ARGS-aggrecan and its association with KOOS
No signiﬁcant associations were seen between SF ARGS levels at
either examination and progression of any of the ﬁve KOOS
dimensions (Table III).
In subjects who decreased in SF ARGS-aggrecan from exami-
nation A to examination B, the likelihood for KOOS pain worsening
between examinations was increased 3.7-fold compared to those
increasing in SF ARGS (OR 3.66, P¼ 0.048; Table III). None of the
other four KOOS dimensions associated with decreasing SF ARGS
(Table III).
Discussion
We showed for this study cohort that 18 years after meniscec-
tomy SF ARGS concentrations were inversely associated with future
loss of joint space in the following 4 e10 years, where low levels
increased the risk of progression and higher levels decreased the
risk11. In the present study we corroborate our earlier ﬁndings by
showing the same inverse association between SF ARGS concen-
trations, but now between ARGS-aggrecan levels at the second
examination 4e10 years later and loss of joint space prior to that
examination. Importantly, we here extend these ﬁndings to show
that, regardless of SF ARGS level at examination A, a decrease in SF
ARGS over the following 4e10 years was associated with a six-fold
increased likelihood of loss of joint space over the same times
period. This estimated risk was not substantially altered by the
addition of osteophyte progression to loss of joint space (a
combination here termed ROA progression), which is in agreement
with our ﬁndings that SF ARGS seems to be unrelated to osteophyte
progression. Within the range of levels seen in these subjects,
having low levels of SFARGS, or having decreasing levels of SFARGS
over time, thus appears to be associated with a higher risk of loss of
joint space. For this patient cohort SF ARGS thus qualiﬁes as marker
prognostic of disease in the Burden of disease, Investigative, Prog-
nostic of disease, Efﬁcacy of intervention, Diagnostic of disease, and
Safety of intervention (BIPEDS) classiﬁcation of OA biomarkers3.
These results may seem inconsistent with multiple previous
reports placing aggrecan degradation as central in OA pathology,
and aggrecanase activity as detrimental to cartilage integrity.
Ablation of aggrecanase activity has been shown to be protective of
OA development in mouse models of OA23,24. Since the ﬁrst
evidence emerging of an aggrecanase being involved in human
joint pathology25,26, aggrecanase activity giving rise to the release
of ARGS-aggrecan from the cartilage has been shown to be
increased above normal under inﬂammatory conditions
in vitro27,28, in inﬂammation in vivo9,10,29, following a knee
trauma9,10,29,30, as well as in subjects with knee OA9,10,29. The SF
concentrations of ARGS-aggrecan in the acute phases of injury orinﬂammation in vivo were in some cases more than 100 times
increased compared to SF of knee healthy subjects9. The levels of SF
ARGS and change in those levels between examinations described
here aremuch lower, and fall within the range of levels found in un-
operated matched reference subjects without meniscus injury11.
With SF levels of the CS846 epitope, (proposed to be present only
on newly synthesised aggrecan31) being elevated two- to three-fold
up to 20 years following a knee injury compared to uninjured32
(suggesting an increased de novo aggrecan synthesis) not only
aggrecan catabolism but also aggrecan anabolism appears to be
affected by knee trauma and arthritis. The relatively small ﬂuctu-
ations in the concentrations of SF ARGS seen in these patients long
after meniscectomy are thus likely to be affected by variations in
both aggrecan synthesis and aggrecanase activity. In contrast, the
extreme elevation in SF ARGS seen in the acute phases of joint
injury or inﬂammation may be due to larger variations in aggre-
canase activity where the effect of variations of aggrecan synthesis
are likely to be overshadowed9,10,29. In the subjects studied here, on
average 18 years after meniscectomy, we hypothesise that the
lower risk for loss of joint space seen in subjects that have higher or
over time increasing levels of SF ARGS, is a reﬂection of a tissue
repair response involving increased synthesis of aggrecan in
combinationwith aggrecanase activity. Increased de novo synthesis
of aggrecan that is in part successfully incorporated in the tissue
and in part degraded by aggrecanase activity resulting in a net
beneﬁcial incorporation, would best explain a lower risk for ROA
progression and a simultaneous release of ARGS-aggrecan.
It appears as if SF ARGS within the low levels found in these
subjects can be interpreted as an anabolic marker (through its
inverse association with loss of joint space). In acute stages of knee
injury and in inﬂammation the marker is elevated many-fold above
normal9,10,29, and appears as a marker of catabolism. This apparent
duality in the interpretation of SF ARGS as a marker, suggests that
a combination of markers of synthesis and degradation is needed
for a better understanding of the processes underlying the release
of proteolytic fragments into SF.
To the best of our knowledge, this study is the ﬁrst to show that
aggrecan ARGS-fragments in SF are associated with pain in human
OA. The correlation between radiographic features of OA and pain is
poor16,33. Others have presented evidence suggesting that aggrecan
fragments may be involved in pain pathogenesis through their
ability to modulate neurite growth34,35. Furthermore, in a mouse
model of OA, ADAMTS-5 deﬁcient mice do not develop mechanical
allodynia associated with OA36. It is therefore possible that the
association between changing SF levels of ARGS-aggrecan and pain
seen in this study may be caused by the aggrecan fragments having
a direct involvement in pain development, as well as indirectly
through loss of joint space (i.e., loss of joint cartilage andmeniscus),
and development of bone marrow lesions37,38.
When studying the association between changing levels of SF
ARGS and progression of our outcomes, we have (in addition to the
adjustments for age, gender, BMI and time between examinations)
included SFARGS levels at examination A in the ﬁnal model. We did
this knowing that SF ARGS levels at examination A showed an
inverse association with loss of joint space11: a decrease from
initially low levels of SF ARGS would have a different starting point
than a decrease from higher levels. To study the effect of the change
itself, we therefore included SF ARGS at examination A in the ﬁnal
model. For transparency, we showORs from the ﬁnal model, as well
as for the crude model and the model adjusted for only age, gender,
BMI, and time between examinations.
This study has several limitations. Only about half of the subjects
included in the study had SF available at both examinations. The
loss of power due to the reduced number of subjects is the reason
why we have not made the regression analysis stratiﬁed for
S. Larsson et al. / Osteoarthritis and Cartilage 20 (2012) 388e395394absence and presence of ROA in the subset, as we previously did for
the larger Study cohort n¼ 14111. Furthermore, we cannot exclude
that variable clearance rates of matrix molecules from the joint
cavitymight inﬂuence the associations noted here, but withmarker
concentrations measured long after trauma a steady state between
markers released into the SF and markers cleared from the SF has
likely occurred39.
In conclusion we found that in middle-aged subjects with
a meniscectomy 18 years earlier, SF ARGS levels were predictive of
disease progression, where decreasing levels of SF ARGS over the
next 4e10 years were associated with an increased risk for loss of
joint space and worsening of knee pain over the same time period.
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